Bogart Wealth’s CRISPR Therapeutics CRSP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$8.3K Hold
150
– – ﹤0.01% 1067
2026
Q2
$8.18K Hold
150
– – ﹤0.01% 1057
2026
Q1
$7.14K Hold
150
– – ﹤0.01% 977
2025
Q4
$7.87K Sell
150
-500
-77% -$29.9K ﹤0.01% 907
2025
Q3
$42.1K Buy
650
+500
+333% +$28.7K ﹤0.01% 500
2025
Q2
$7.3K Buy
150
+50
+50% +$1.94K ﹤0.01% 853
2025
Q1
$3.4K Buy
+100
New +$4.24K ﹤0.01% 975
2024
Q4
– Sell
-500
Closed -$23.5K – 1348
2024
Q3
$23.5K Hold
500
– – ﹤0.01% 528
2024
Q2
$27K Buy
+500
New +$28.9K ﹤0.01% 489
2023
Q2
– Sell
-6
Closed -$271 – 1061
2023
Q1
$271 Hold
6
– – ﹤0.01% 1067
2022
Q4
$244 Sell
6
-44
-88% -$2.33K ﹤0.01% 953
2022
Q3
$3K Buy
+50
New +$3.62K ﹤0.01% 766

Other funds holding CRSP

Bogart Wealth's CRSP Position: Q3 2026 in Review

Bogart Wealth held its CRISPR Therapeutics (CRSP) position steady in Q3 2026 at 150 shares worth $8.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1067.

Bogart Wealth first reported a position in CRSP in Q3 2022 and has held it in 12 quarters since. The position peaked at $42.1K in Q3 2025. 502 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

  • Bogart Wealth held 150 shares of CRISPR Therapeutics worth $8.3K as of Q3 2026.
  • Bogart Wealth left its CRISPR Therapeutics share count unchanged in Q3 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Bogart Wealth's portfolio in Q3 2026, its #1067 holding.
  • Bogart Wealth first reported a position in CRISPR Therapeutics in Q3 2022 and has held it in 12 quarters since.
  • Bogart Wealth's CRISPR Therapeutics position peaked at $42.1K in Q3 2025.
  • 502 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on Bogart Wealth's 13F filing for Q3 2026, filed 10 Nov 2026.